CAD Helps Radiologists ID Small Breast Cancers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 9
Volume 9
Issue 9

ATLANTA-In a retrospective review of more than 12,000 screening mammograms, computer technology found 52% of missed cancers, Kunio Doi, PhD, reported at the Era of Hope meeting, featuring research sponsored by the US Department of Defense Breast Cancer Research Program.

ATLANTA—In a retrospective review of more than 12,000 screening mammograms, computer technology found 52% of missed cancers, Kunio Doi, PhD, reported at the Era of Hope meeting, featuring research sponsored by the US Department of Defense Breast Cancer Research Program.

“Computer-aided diagnosis [CAD] cannot pick up lesions that are invisible at mammography, but it can compensate for some cases of radiologist oversight,” said Dr. Doi, professor of radiology, University of Chicago. “We believe the increasingly positive results with CAD demonstrate it can serve as a ‘second opinion’ for traditional screening mammograms.”

In this study, a CAD Prototype Intelligent Workstation, developed by Dr. Doi and his colleagues, was used to review the mammograms of more than 22,000 women who had routine screenings in the past 5 years.

Among the first 12,670 women whose charts were analyzed during the first 3 years, 79 developed breast cancer. Of these 79 cancer patients, 42 had a negative prior screening mammogram. Retrospective review of these cases showed that 19 were not visible on mammography, but of the 23 cases that had a subtle lesion visible in retrospect, the computer identified 12 of them. “The CAD workstation identified 52% of these missed cancers roughly a year before they were actually detected,” Dr. Doi said.

Under subcontract from the University’s Department of Defense grant, radiologists are now using CAD as a concurrent second opinion for all screening mammograms performed at Grant Square Imaging, La Grange Memorial Hospital, Hinsdale, Illinois. The center is using the R2 Technology M1000 ImageChecker, the only CAD device FDA approved to date.

The radiologists are recording all

cases in which information from the ImageChecker results in additional patient evaluation (that is, evaluation for findings not originally perceived by the radiologist). Data analysis from that study will begin in about 2 years, Dr. Doi said.

“The next challenge for CAD is diagnosis,” Dr. Doi said. “We have already developed algorithms that guide our system in distinguishing benign from malignant lesions. I believe that in time, as we fine-tune those algorithms, CAD will also become an important tool in helping women avoid unnecessary biopsies in addition to diagnosing more cancers.”

How CAD Works

With the CAD Intelligent Workstation, a laser scanner first transforms the mammography film into a detailed matrix of digital data. Microcalcifications appear as tiny white spots, and masses appear as round or irregular shapes.

Guided by complex programming refined over many years, the system’s computer vision and artificial intelligence algorithms scan the digital matrix, sift out background findings and normal soft tissue, then highlight patterns likely to represent lesions.

To detect masses, the computer looks for a deviation from the normal architectural symmetry of the right and left breasts, using a bilateral-subtraction technique.

To detect clustered microcalcifications, the digitalized mammogram is processed by a linear filter to improve the signal-to-noise ratio of microcalcifications on the image. Other techniques are then used to extract potential signal sites from the noise background and distinguish true signals from noise or artifacts.

Areas interpreted as suspicious for either masses or microcalcifications are flagged with arrows (see Figure). After reviewing the mammograms and the computer output, a radiologist prepares a report based on experienced judgment.

A service is now available to provide physicians and mammography centers worldwide with access to CAD technology. A company called iMammogram.com Inc. (Westlake Village, California) will collect and return mammographic films by bonded courier, perform the CAD analysis (which it calls CloserLook), and provide a digital archive for each patient.

The company’s website, located at www.imammogram.com, provides case studies showing the potential benefits of CAD review . In one example, CloserLook review with the ImageChecker found a cancer in the left breast on a woman’s annual mammogram. Retrospective computer review showed that the lesion was present on the woman’s prior mammogram performed 16 months earlier.

The company has also signed an agreement with General Electric Medical Systems to develop a system that will allow mammography centers to transmit images to iMammogram’s facility electronically rather than by courier.

ONI will provide a fuller report on iMammogram.com and its teleradiology project in an upcoming issue.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.